Conference Reports for NATAP

Back

Digestive Disease Week (DDW) New Orleans, LA May 15-20, 2004     Doctors Conclude Majority of Both HCV & Coinfected Not Elgible for IFN/RBV (05/16/04)   MMPD (new HCV Drug), Pegasys, & Ribavirin Study (05/16/04)   NM283: new oral HCV drug, polymerase inhibitor (05/16/04)   Significant and Sustained Efficacy of Adefovir After 4 Years of Treatment in Chronic HBV Patients with Lamivudine-Resistant HBV and HIV Coinfection (05/16/04)   Three year Results from a Double-Blind, Randomized, Pacebo-Controlled, Study of Adefovir (ADV) in HBeAg-negative Chronic Hepatitis B (CHB) (05/16/04)   "Combination of Pegylated IFN and Lamivudine is superior to Lamivudine alone in the treatment of HBV" (05/16/04)   Study Examines HCV & Mistletoe & Herbal Concoction, When Interferon Fails (05/16/04)   Coffee, Caffeine Consumption Associated With Reduced Liver Disease (05/16/04)   ADEFOVIR RESISTANCE REPORT (05/16/04)   Adefovir Reduced HBV Viral Reservoir & HBsAg in Parallel (05/16/04)   Consensus Interferon for Nonresponders- revisited (05/16/04)   Consensus Interferon in Peg/RBV Nonresponders (05/15/04)   Twice Weekly Higher Dosing of PegIntron Had Better Viral Response Rates in Genotype 1 Patients (05/15/04)   Viramidine May Not Lead to Ribavirin Associated Anemia: "Clinical Study of Viramidine in Treatment of Hepatitis C Supports RBC-Sparing Mechanisms of Action" (05/15/04)